MannKind Receives $30.6 Million From Sanofi VALE
Post# of 301275
VALENCIA, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD ) (TASE: MNKD ) today confirmed that it received $30.6 million from Sanofi on January 6, 2017, representing the balance of the accelerated insulin “put” option previously exercised by MannKind. This payment was made pursuant to a previously disclosed agreement reached with Sanofi on November 9, 2016.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD ) (TASE: MNKD ) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP, Finance 661-775-5300 ralinaya@mannkindcorp.com
(0)
(0)